Clinical Trials

Our clinical development program is focused on improving the lives of cancer patients utilizing innovative approaches either in monotherapy or in combination with existing therapies.

Study

Indication

Combination

Phase I

Phase II

Pivotal

Resminostat

Assorted studies

Assorted cancers

– / Chemotherapy

RESMAIN

Cutaneous T-cell Lymphoma (CTCL)

BTC*

Biliary tract cancer

S1 Chemotherapy

Domatinostat

TOPAS

Hematologic malignancies

SENSITIZE

CI refractory or non-responsive melanoma

CI

EMERGE**

CI non-responsive MSS gastro-intestinal cancer

CI

MERKLIN 1

CI naïve Merkel cell carcinoma (MCC)

CI

MERKLIN 2

CI refractory/relapsed Merkel cell carcinoma (MCC)

CI

DONIMI**

Melanoma, neo-adjuvant

CI

„Triple Combo“**

Melanoma

CI + CI

* Performed by 4SC’s partner Yakult Honsha; ** Investigator-sponsored trial; CI: Checkpoint inhibitor, a specific type of immunotherapy; MSS: Microsatellite stable; dark blue: completed; middle blue: ongoing; light blue: in preparation, grey: planned.

Share this page:

Follow us on: